CBX7

Summary

CBX7 (chromobox 7, HGNC:1557) is a protein-coding gene on chromosome 22q13.1, encoding Chromobox protein homolog 7 (O95931). Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development.

This gene encodes a protein that contains the CHROMO (CHRomatin Organization MOdifier) domain. The encoded protein is a component of the Polycomb repressive complex 1 (PRC1), and is thought to control the lifespan of several normal human cells.

Source: NCBI Gene 23492 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 42 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_175709

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1557
Approved symbol	CBX7
Name	chromobox 7
Location	22q13.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000100307
Ensembl biotype	protein_coding
OMIM	608457
Entrez	23492

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 16 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000216133, ENST00000401405, ENST00000434260, ENST00000475962, ENST00000477827, ENST00000482294, ENST00000490741, ENST00000858776, ENST00000858777, ENST00000858778, ENST00000858779, ENST00000858780, ENST00000858781, ENST00000858782, ENST00000858783, ENST00000858784, ENST00000944728, ENST00000944729, ENST00000944730, ENST00000944731

RefSeq mRNA: 3 — MANE Select: NM_175709 NM_001346743, NM_001346744, NM_175709

CCDS: CCDS13986, CCDS87028

Canonical transcript exons

ENST00000216133 — 6 exons

Exon	Start	End
ENSE00000654684	39134401	39134752
ENSE00001299764	39130772	39134048
ENSE00001308314	39138636	39138702
ENSE00001330607	39141371	39141436
ENSE00001934950	39152376	39152680
ENSE00003660526	39149789	39149832

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 98.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.7980 / max 184.0461, expressed in 1513 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
194270	5.6300	1238
194271	3.3853	817
194269	0.5762	254
194268	0.2066	134

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	98.57	gold quality
paraflocculus	UBERON:0005351	98.50	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.64	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.33	gold quality
frontal pole	UBERON:0002795	97.29	gold quality
cerebellar cortex	UBERON:0002129	97.28	gold quality
cerebellar hemisphere	UBERON:0002245	97.28	gold quality
mucosa of stomach	UBERON:0001199	97.23	gold quality
cerebellum	UBERON:0002037	97.18	gold quality
pons	UBERON:0000988	97.14	gold quality
middle frontal gyrus	UBERON:0002702	97.14	gold quality
right coronary artery	UBERON:0001625	97.02	gold quality
right frontal lobe	UBERON:0002810	96.94	gold quality
popliteal artery	UBERON:0002250	96.89	gold quality
tibial artery	UBERON:0007610	96.89	gold quality
prefrontal cortex	UBERON:0000451	96.84	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.73	gold quality
lower esophagus	UBERON:0013473	96.67	gold quality
parietal lobe	UBERON:0001872	96.64	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.52	gold quality
postcentral gyrus	UBERON:0002581	96.51	gold quality
superior vestibular nucleus	UBERON:0007227	96.50	gold quality
frontal cortex	UBERON:0001870	96.41	gold quality
cingulate cortex	UBERON:0003027	96.41	gold quality
frontal lobe	UBERON:0016525	96.41	gold quality
anterior cingulate cortex	UBERON:0009835	96.38	gold quality
saphenous vein	UBERON:0007318	96.34	gold quality
occipital lobe	UBERON:0002021	96.30	gold quality
olfactory bulb	UBERON:0002264	96.27	gold quality
aorta	UBERON:0000947	96.24	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.13

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CCNE1	Repression
CDH1	Activation

miRNA regulators (miRDB)

142 targeting CBX7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4799-5P	99.82	70.60	2663

Literature-anchored findings (GeneRIF, showing 40)

• controls cellular lifespan through regulation of both the p16(Ink4a)/Rb and the Arf/p53 pathways (PMID:14647293)
• CBX7 is a chromobox protein causally linked to cancer development (PMID:17374722)
• In human glioma, CBX7 is down-regulated by the inhibition of miR-9 at posttranscriptional level. (PMID:18686603)
• Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer (PMID:18701502)
• Downregulation of CBX7 is associated with urothelial tumor progression. (PMID:18984978)
• the ability of CBX7 to positively regulate E-cadherin expression by interacting with HDAC2 and inhibiting its activity on the E-cadherin promoter would account for the correlation between the loss of CBX7 expression and a highly malignant phenotype (PMID:19706751)
• Data show that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. (PMID:20541999)
• data reported indicate that the evaluation of CBX7 expression may represent a valid tool in the prognosis of colon cancer since a reduced survival of colorectal cancer patients is associated with the loss of CBX7 expression. (PMID:20542683)
• CBX7 acts as an oncogene in the carcinogenesis and progression of gastric cancer, and it may regulate tumorigenesis, cell migration and cancer metastasis partially via p16(INK4a) regulatory pathway. (PMID:20723236)
• found that expression of CBX7 in gastric carcinoma tissues with p16 methylation was significantly lower than that in their corresponding normal tissues, which showed a negative correlation with transcription of p16 in gastric mucosa (PMID:21060834)
• cbx7 expression was significantly downregulated in multiple human cancer tissues. (PMID:22041561)
• These data suggest that CBX7 is a tumor suppressor and that its loss plays a key role in the pathogenesis of cancer. (PMID:22214847)
• MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation. (PMID:22226354)
• we showed for the first time that CBX7 was associated with a decreased prognosis for clear cell adenocarcinoma of the ovary (PMID:24375438)
• Results suggest that the loss of CBX7 expression might play a critical role in advanced stages of carcinogenesis by deregulating the expression of specific effector genes. (PMID:24865347)
• CBX7-mediated epigenetic induction of DKK-1 is crucial for the inhibition of breast tumorigenicity, suggesting that CBX7 could be a potential tumor suppressor in breast cancer. (PMID:25351982)
• CBX7/HMGA1b/NF-kappaB could take part in the same transcriptional mechanism that finally leads to the regulation of SPP1 gene expression in papillary thyroid carcinoma. (PMID:25595895)
• Aberrantly expressed miR-9 contributes to T24 cells invasion, partly through directly down-regulating CBX7 protein expression in bladder transitional cell carcinoma (PMID:25596753)
• Cbx7 is downregulated in CCs, and Cbx7 expression-low tumors correlated with lymph metastasis and poor overall survival of CC patients. (PMID:25881303)
• these results suggest that the retention of CBX7 expression may play a role in the modulation of chemosensitivity of lung cancer patients to the treatment with irinotecan and etoposide (PMID:26216446)
• Data show that polycomb-group proteins BMI1, PHC3, CBX6 and CBX7 expression was significantly increased during imatinib treatment. (PMID:26343356)
• the miR-9 family of microRNAs (miRNAS) downregulates the expression of CBX7. In turn, CBX7 represses miR-9-1 and miR-9-2 as part of a regulatory negative feedback loop. (PMID:26416703)
• Study found that Cbx7 was downregulated in glioma cell lines and tumors and identifies it as an inhibitor of glioma cell migration through its inhibitory effect on YAP/TAZ-CTGF-hippo signaling axis and underscores the importance of epigenetic inactivation of Cbx7 in gliomagenesis. (PMID:27291091)
• Data suggest that miR-375 leads to the activation of oncogenic signatures and tumor progression by targeting chromobox homolog 7 protein (CBX7). (PMID:27449098)
• Suggest CBX7 is an important tumor suppressor that negatively modulates PTEN/Akt signaling during pancreatic tumorigenesis. (PMID:28030829)
• CBX7 inhibits epithelial-to-mesenchymal transformation and invasion in glioma (PMID:28388562)
• our results validate the assumption that CBX7 is a tumor suppressor of gliomas. Moreover, CBX7 is a potential and novel prognostic biomarker in glioma patients. We also clarified that CBX7 silences CCNE1 via the combination of CCNE1 promoter and the recruitment of HDAC2. (PMID:28460453)
• CBX7 positively regulates stem cell-like characteristics of gastric cancer cells by inhibiting p16 and activating AKT-NF-kappaB-miR-21 pathway. (PMID:29422082)
• Potential role of CBX7 in regulating pluripotency of adult human pluripotent-like olfactory stem cells in stroke model has been demonstrated. (PMID:29717132)
• Mass spectrometry analysis revealed several non-histone protein interactions between CBX7 and the H3K9 methyltransferases SETDB1, EHMT1, and EHMT2. These CBX7-binding proteins possess a trimethylated lysine peptide motif highly similar to the canonical CBX7 target H3K27me3. (PMID:30759399)
• CBX7 and PRMT1 contribute to regulate E-cadherin expression through several mechanisms. (PMID:30826432)
• Decreased CBX7 expression levels were correlated with liver cirrhosis in HCC patients. Furthermore, the survival times of HCC patients who were CBX7-expression-negative were shorter than HCC patients who were CBX7-expression-positive. Results show that downregulation of CBX7 is related to HCC progression and a poor prognosis in HCC patients. (PMID:30990338)
• findings suggest that CBX4 rs2289728 and CBX7 rs139394 are protective SNPs against HCC. The two SNPs may reduce the risk of HCC while suppressing the expression of CBX4 and CBX7. (PMID:31211140)
• CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. (PMID:32205869)
• MicroRNA-18a suppresses ovarian carcinoma progression by targeting CBX7 and regulating ERK/MAPK signaling pathway and epithelial-to-mesenchymal transition. (PMID:32495862)
• Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer. (PMID:33400401)
• CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. (PMID:34035231)
• Expression and correlation analysis of Skp2 and CBX7 in cervical cancer. (PMID:34281957)
• CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer. (PMID:35526483)
• Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes. (PMID:37553450)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cbx7a	ENSDARG00000038025
danio_rerio	cbx7b	ENSDARG00000087181
mus_musculus	Cbx7	ENSMUSG00000053411
rattus_norvegicus	Cbx7	ENSRNOG00000016875
caenorhabditis_elegans		WBGENE00001995
caenorhabditis_elegans		WBGENE00007615

Paralogs (8): CBX5 (ENSG00000094916), CBX1 (ENSG00000108468), CBX3 (ENSG00000122565), CBX8 (ENSG00000141570), CBX4 (ENSG00000141582), CBX2 (ENSG00000173894), CBX6 (ENSG00000183741), NPTXR (ENSG00000221890)

Protein

Protein identifiers

Chromobox protein homolog 7 — O95931 (reviewed: O95931)

All UniProt accessions (3): O95931, B0QYP2, B0QYP3

UniProt curated annotations — full annotation on UniProt →

Function. Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A ‘Lys-119’, rendering chromatin heritably changed in its expressibility. Promotes histone H3 trimethylation at ‘Lys-9’ (H3K9me3). Binds to trimethylated lysine residues in histones, and possibly also other proteins. Regulator of cellular lifespan by maintaining the repression of CDKN2A, but not by inducing telomerase activity.

Subunit / interactions. Component of a PRC1-like complex. Interacts with RING1 and RNF2/RING1B, but not with BMI1, EED or EZH2. Interacts with PCGF1, PCGF2, PCGF3, PCGF5 and PCGF6.

Subcellular location. Nucleus.

Miscellaneous. The human orthologuous proteins of Drosophila Polycomb group protein Pc, CBX2, CBX4, CBX6, CBX7 and CBX8, show distinct nuclear localizations, contribute differently to transcriptional repression, and appear to be part of distinct PRC1-like protein complexes.

RefSeq proteins (3): NP_001333672, NP_001333673, NP_783640* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000953	Chromo/chromo_shadow_dom	Domain
IPR016197	Chromo-like_dom_sf	Homologous_superfamily
IPR017984	Chromo_dom_subgr	Domain
IPR023779	Chromodomain_CS	Conserved_site
IPR023780	Chromo_domain	Domain
IPR033773	CBX7_C	Conserved_site
IPR043000	CBX7	Family

Pfam: PF00385, PF17218

UniProt features (19 total): strand 5, mutagenesis site 4, helix 3, region of interest 2, sequence conflict 2, chain 1, domain 1, turn 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
8SII	X-RAY DIFFRACTION	1.37
4MN3	X-RAY DIFFRACTION	1.54
5EPJ	X-RAY DIFFRACTION	1.6
6V2R	X-RAY DIFFRACTION	1.6
3GS2	X-RAY DIFFRACTION	1.7
2K1B	SOLUTION NMR
2L12	SOLUTION NMR
2L1B	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95931-F1	67.01	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (4):

Position	Phenotype
31	loss of cellular lifespan extension.
32	loss of cellular lifespan extension.
234	loss of interaction with rnf2.
244	reduced interaction with rnf2.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 239 (showing top): RRAGTTGT_UNKNOWN, FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN, ZHAN_MULTIPLE_MYELOMA_PR_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, HNF4_01, VANHARANTA_UTERINE_FIBROID_DN, AACTTT_UNKNOWN, TCCAGAG_MIR518C, GOCC_NUCLEAR_UBIQUITIN_LIGASE_COMPLEX, GCM_MAPK10, YAMAZAKI_TCEB3_TARGETS_DN, GOBP_CHROMATIN_REMODELING, GTGACTT_MIR224, GOBP_HETEROCHROMATIN_ORGANIZATION

GO Biological Process (2): negative regulation of transcription by RNA polymerase II (GO:0000122), chromatin organization (GO:0006325)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), PcG protein complex (GO:0031519), PRC1 complex (GO:0035102)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cellular component organization	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
nuclear protein-containing complex	1
nuclear ubiquitin ligase complex	1
PcG protein complex	1

Protein interactions and networks

STRING

1099 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CBX7	BMI1	P35226	992
CBX7	R4GMX3	R4GMX3	992
CBX7	RING1	Q06587	989
CBX7	EZH2	Q15910	964
CBX7	SUZ12	Q15022	957
CBX7	CBX8	Q9HC52	941
CBX7	RNF2	Q99496	938
CBX7	HDAC2	Q92769	906
CBX7	CBX4	O00257	875
CBX7	PCGF2	P35227	871
CBX7	CBX2	Q14781	865
CBX7	KDM2B	Q8NHM5	831
CBX7	CDKN2A	P42771	810
CBX7	RYBP	Q8N488	795
CBX7	PHC2	Q8IXK0	746

IntAct

61 interactions, top by confidence:

A	B	Type	Score
RNF2	CBX7	psi-mi:“MI:0407”(direct interaction)	0.960
RNF2	CBX7	psi-mi:“MI:0915”(physical association)	0.960
BMI1	CBX7	psi-mi:“MI:0914”(association)	0.940
CBX7	BMI1	psi-mi:“MI:0914”(association)	0.940
CBX7	BMI1	psi-mi:“MI:0915”(physical association)	0.940
BMI1	CBX7	psi-mi:“MI:0407”(direct interaction)	0.940
BMI1	CBX7	psi-mi:“MI:0915”(physical association)	0.940
BMI1	CBX4	psi-mi:“MI:0914”(association)	0.900
PCGF2	CBX4	psi-mi:“MI:0914”(association)	0.840
CBX7	PCGF2	psi-mi:“MI:0407”(direct interaction)	0.840
CBX7	PCGF2	psi-mi:“MI:0915”(physical association)	0.840
PHC1	CBX4	psi-mi:“MI:0914”(association)	0.790

BioGRID (127): CBX7 (Affinity Capture-MS), CBX7 (Affinity Capture-MS), PHC3 (Affinity Capture-MS), PHC2 (Affinity Capture-MS), USP20 (Affinity Capture-MS), BCOR (Affinity Capture-MS), CSNK2B (Affinity Capture-MS), RNF2 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF6 (Affinity Capture-MS), BMI1 (Affinity Capture-MS), PCGF3 (Affinity Capture-MS), CBX7 (Affinity Capture-MS), CBX7 (Affinity Capture-Western), USP20 (Affinity Capture-MS)

ESM2 similar proteins: A0JPN4, A2AKB4, A6NDY0, A6NP61, A7E321, B0BNE4, B1ASB6, O54824, O88286, O95931, P60924, Q14005, Q14154, Q1XFL1, Q3T1H2, Q3TYG6, Q3ZBR0, Q49AM3, Q4R2Z8, Q4R747, Q4VXA5, Q5R7E7, Q5SU73, Q5SXM2, Q5SYB0, Q5XFR0, Q6NVP7, Q6P1D7, Q6ZUX3, Q7Z572, Q7ZXB8, Q80VM8, Q8BG34, Q8BIY3, Q8BLK9, Q8BP86, Q8IY92, Q8K124, Q93075, Q96FV0

Diamond homologs: A0A0P0VUY4, G3V8T1, O60016, O95931, P05205, P23198, P29227, P30658, P45968, P45973, P60889, P83916, P83917, Q10103, Q13185, Q14781, Q3TYA6, Q5F3W5, Q5KQL9, Q5R6X7, Q61686, Q6AYK9, Q8N8U2, Q8VDS3, Q94F87, Q99549, Q9AXT8, Q9D5D8, Q9WTK2, Q9Y232, Q9Y6F7, Q9Y6F8, G5EDE2, G5EET5, O00257, O43463, O54864, O55187, O95503, P26017

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CBX7	“up-regulates quantity by expression”	CDH1	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 23 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of DNA methylation proteins	9	287.9×	1e-19
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	10	143.1×	8e-19
SUMOylation of transcription cofactors	9	104.1×	2e-15
SUMOylation of RNA binding proteins	9	102.0×	2e-15
Transcriptional Regulation by E2F6	7	97.6×	5e-12
Regulation of PTEN gene transcription	9	76.5×	2e-14
SUMOylation of chromatin organization proteins	9	68.0×	5e-14
SUMOylation of DNA damage response and repair proteins	9	62.8×	9e-14

GO biological processes:

GO term	Partners	Fold	FDR
chromatin remodeling	7	22.2×	2e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1331 predictions. Top by Δscore:

Variant	Effect	Δscore
22:39133899:T:TA	donor_gain	1.0000
22:39133900:C:A	donor_gain	1.0000
22:39134058:C:CT	acceptor_gain	1.0000
22:39134399:AC:A	donor_gain	1.0000
22:39134399:ACCCT:A	donor_gain	1.0000
22:39134400:CC:C	donor_gain	1.0000
22:39134400:CCCTC:C	donor_gain	1.0000
22:39134403:T:A	donor_gain	1.0000
22:39141369:A:AC	donor_gain	1.0000
22:39141370:C:CC	donor_gain	1.0000
22:39141370:CTT:C	donor_gain	1.0000
22:39141370:CTTCT:C	donor_gain	1.0000
22:39141372:T:TA	donor_gain	1.0000
22:39141437:CTGG:C	acceptor_loss	1.0000
22:39141438:T:C	acceptor_loss	1.0000
22:39149787:A:AC	donor_gain	1.0000
22:39149788:C:CC	donor_gain	1.0000
22:39152371:CTCA:C	donor_loss	1.0000
22:39152373:CAC:C	donor_loss	1.0000
22:39152378:T:A	donor_gain	1.0000
22:39133899:TCCC:T	donor_gain	0.9900
22:39134046:CTG:C	acceptor_gain	0.9900
22:39134055:C:CT	acceptor_gain	0.9900
22:39134399:A:AC	donor_gain	0.9900
22:39134400:C:CC	donor_gain	0.9900
22:39134400:CCCT:C	donor_gain	0.9900
22:39141374:T:A	donor_gain	0.9900
22:39141381:AGG:A	donor_gain	0.9900
22:39141437:C:CC	acceptor_gain	0.9900
22:39149052:C:CA	donor_gain	0.9900

AlphaMissense

1608 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:39141407:A:G	I48T	1.000
22:39141407:A:T	I48N	1.000
22:39141424:C:A	W42C	1.000
22:39141424:C:G	W42C	1.000
22:39141425:C:G	W42S	1.000
22:39141426:A:G	W42R	1.000
22:39141426:A:T	W42R	1.000
22:39149799:A:G	W35R	1.000
22:39149799:A:T	W35R	1.000
22:39149806:C:A	W32C	1.000
22:39149806:C:G	W32C	1.000
22:39149807:C:G	W32S	1.000
22:39149808:A:G	W32R	1.000
22:39149808:A:T	W32R	1.000
22:39149819:T:G	Y28S	1.000
22:39149820:A:C	Y28D	1.000
22:39149820:A:G	Y28H	1.000
22:39152398:A:T	I16N	1.000
22:39152412:G:C	F11L	1.000
22:39152412:G:T	F11L	1.000
22:39152413:A:G	F11S	1.000
22:39152414:A:G	F11L	1.000
22:39133952:A:T	V232D	0.999
22:39141392:A:G	L53P	0.999
22:39141392:A:T	L53H	0.999
22:39141404:A:G	L49S	0.999
22:39141407:A:C	I48S	0.999
22:39141425:C:A	W42L	0.999
22:39141426:A:C	W42G	0.999
22:39141430:G:C	S40R	0.999

dbSNP variants (sampled 300 via entrez): RS1000032566 (22:39139062 A>G), RS1000077771 (22:39146085 G>A), RS1000295982 (22:39140252 C>T), RS1000358300 (22:39135452 A>C), RS1000373209 (22:39132630 G>A), RS1000502567 (22:39148361 A>G), RS1000535206 (22:39138438 G>A,C), RS1000582245 (22:39130405 C>T), RS1000604872 (22:39137383 T>C,G), RS1000696134 (22:39136461 G>T), RS1000708930 (22:39133651 C>T), RS1000725276 (22:39136613 C>A), RS1000946576 (22:39131648 G>A), RS1001013063 (22:39153509 C>T), RS1001200016 (22:39136495 T>C)

Disease associations

OMIM: gene MIM:608457 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST002140_6	Multiple myeloma	8.000000e-16
GCST002541_121	Menarche (age at onset)	3.000000e-08
GCST002921_8	Multiple myeloma	3.000000e-07
GCST002922_9	Multiple myeloma and monoclonal gammopathy	9.000000e-06
GCST004028_10	Immunoglobulin light chain (AL) amyloidosis	8.000000e-08
GCST004610_103	White blood cell count	1.000000e-09
GCST004627_117	Lymphocyte count	2.000000e-16
GCST012396_13	Multiple myeloma	1.000000e-09
GCST90002383_110	Hematocrit	4.000000e-12
GCST90002384_506	Hemoglobin	7.000000e-12
GCST90002388_270	Lymphocyte count	1.000000e-37
GCST90002398_28	Neutrophil count	1.000000e-10
GCST90002407_199	White blood cell count	1.000000e-14

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0004587	lymphocyte count
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0004833	neutrophil count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1764946 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 36,848 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL265502	SURAMIN	3	36,848

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

92 potent at pChembl≥5 of 172 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.96	Kd	11	nM	CHEMBL4647581
7.92	Kd	12	nM	CHEMBL3780251
7.70	IC50	20	nM	CHEMBL5715919
7.50	IC50	32	nM	CHEMBL3972289
7.46	IC50	35	nM	CHEMBL3958557
7.46	IC50	35	nM	CHEMBL3889586
7.43	IC50	37	nM	CHEMBL3939958
7.33	IC50	47	nM	CHEMBL3942693
7.27	Kd	53.8	nM	CHEMBL5715919
7.25	IC50	56	nM	CHEMBL3916023
7.23	Kd	59	nM	CHEMBL5715919
7.21	IC50	61	nM	CHEMBL3934881
7.20	IC50	63	nM	CHEMBL3987134
7.12	IC50	75	nM	CHEMBL3969494
7.09	IC50	81	nM	CHEMBL3953637
7.01	Kd	97	nM	CHEMBL3939958
7.01	Kd	97	nM	CHEMBL4449240
7.00	Kd	100	nM	CHEMBL3780251
6.89	IC50	130	nM	CHEMBL3933207
6.80	Kd	160	nM	CHEMBL3780663
6.80	Kd	160	nM	CHEMBL4635096
6.70	Kd	200	nM	CHEMBL3234442
6.70	Kd	200	nM	CHEMBL3234443
6.66	Kd	220	nM	CHEMBL3559502
6.66	IC50	220	nM	CHEMBL3925993
6.64	IC50	230	nM	CHEMBL3973366
6.62	IC50	240	nM	CHEMBL3898460
6.60	IC50	250	nM	CHEMBL3937936
6.55	Kd	280	nM	CHEMBL3234188
6.54	Kd	290	nM	CHEMBL3780663
6.52	Kd	300	nM	CHEMBL4640223
6.40	Kd	400	nM	CHEMBL3780712
6.24	IC50	570	nM	CHEMBL3943850
6.16	Kd	700	nM	CHEMBL4646516
6.13	IC50	740	nM	CHEMBL3944916
5.96	IC50	1100	nM	CHEMBL3978944
5.96	IC50	1100	nM	CHEMBL4640937
5.92	IC50	1200	nM	CHEMBL3935965
5.82	Kd	1500	nM	CHEMBL4643012
5.82	Kd	1500	nM	CHEMBL4640186
5.80	Kd	1600	nM	CHEMBL4637043
5.77	IC50	1700	nM	CHEMBL3781271
5.77	IC50	1700	nM	CHEMBL3949885
5.75	Kd	1770	nM	CHEMBL3234145
5.70	Kd	2000	nM	CHEMBL3234136
5.70	IC50	2000	nM	CHEMBL4642464
5.64	IC50	2300	nM	CHEMBL3781271
5.62	Kd	2400	nM	CHEMBL4588523
5.58	IC50	2600	nM	CHEMBL3980951
5.55	Kd	2800	nM	CHEMBL4469115

PubChem BioAssay actives

86 with measured affinity, of 334 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	0.0110	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	0.0120	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[propan-2-yl(propyl)amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0320	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[ethyl(propan-2-yl)amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0350	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0350	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0370	uM
4-tert-butyl-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-(diethylamino)-1-[[(2S)-1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0470	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0560	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-3-phenyl-2-[(4-propan-2-ylbenzoyl)amino]propanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0610	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-[4-(aminomethyl)phenyl]-2-[(4-tert-butylbenzoyl)amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0630	uM
4-tert-butyl-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-(diethylamino)-1-(2-hydroxyethylamino)-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0750	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-ethylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0810	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1578929: Inhibition of CBX7 (unknown origin) assessed as dissociation constant by isothermal titration calorimetry	kd	0.0970	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoic acid	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1300	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-amino-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1288276: Binding affinity to N-terminal His6-tagged human CBX7 (8 to 62 residues) expressed in Escherichia coli BL21 by surface plasmon resonance assay	kd	0.1600	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]-2-cyclopentylacetyl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	0.1600	uM
[(5S)-6-[[(2R)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-cyclopentyl-2-[[(2S)-2-[[(2S)-2-[(4-methoxycarbonylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]acetyl]amino]-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	0.2000	uM
[(5S)-5-[[(2S)-2-cyclopentyl-2-[[(2S)-2-[[(2S)-2-[(4-methoxycarbonylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]acetyl]amino]-6-(1,3-dihydroxypropan-2-ylamino)-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	0.2000	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(4-methylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2200	uM
[(5S)-6-(2-aminoethylamino)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-2-cyclopentylacetyl]amino]-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	0.2200	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-3-phenyl-2-[[4-(trifluoromethyl)benzoyl]amino]propanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2300	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2400	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-methoxybenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2500	uM
[(5S)-6-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	0.2800	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	0.3000	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1288269: Binding affinity to N-terminal His6-tagged human CBX7 (8 to 62) expressed in Escherichia coli BL21 using FITC-peptide-3 as competitive binding probe by fluorescence polarization assay	kd	0.4000	uM
methyl 4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-(diethylamino)-1-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]benzoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.5700	uM
[(5S)-6-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[3-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]propanoylamino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	0.7000	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(3-methylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.7400	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(2-naphthalen-2-ylacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	1.1000	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1650081: Inhibition of CBX7 (unknown origin) assessed as inhibition of CBX4 disruption by competitive FP assay	ic50	1.1000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-benzamido-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	1.2000	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	1.5000	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]-2-cyclopentylacetyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	1.5000	uM
[(5S)-6-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[3-[[3-carboxy-4-(3-hydroxy-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]propanoylamino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-oxohexyl]-trimethylazanium	1650078: Binding affinity to CBX7 (unknown origin) assessed as dissociation constant by fluorescence polarization analysis	kd	1.6000	uM
[(5S)-6-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1288269: Binding affinity to N-terminal His6-tagged human CBX7 (8 to 62) expressed in Escherichia coli BL21 using FITC-peptide-3 as competitive binding probe by fluorescence polarization assay	ic50	1.7000	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-(1H-indol-3-yl)acetyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	1.7000	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	1.7700	uM
[(5S)-6-[[(2S)-1-[[(2S)-1-amino-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-bromobenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]-trimethylazanium	1650081: Inhibition of CBX7 (unknown origin) assessed as inhibition of CBX4 disruption by competitive FP assay	ic50	2.0000	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	2.0000	uM
3-hydroxy-1-methyl-3-(2-naphthalen-1-yl-2-oxoethyl)indol-2-one	1565817: Binding affinity to recombinant human N-terminal GST-tagged CBX7 (1 to 62 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	2.4000	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-benzamido-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	2.6000	uM
3-[2-[4-(diethylamino)piperidin-1-yl]-2-oxoethyl]-5-fluoro-1,3-benzoxazol-2-one	1565817: Binding affinity to recombinant human N-terminal GST-tagged CBX7 (1 to 62 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	2.8000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	3.1000	uM
5-fluoro-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1,3-benzoxazol-2-one	1565817: Binding affinity to recombinant human N-terminal GST-tagged CBX7 (1 to 62 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	3.4000	uM
3-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-5-methoxy-1,3-benzoxazol-2-one	1565817: Binding affinity to recombinant human N-terminal GST-tagged CBX7 (1 to 62 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	3.9000	uM
[(5S)-5-[[(2S)-2-cyclopentyl-2-[[(2S)-2-[(2-phenylacetyl)amino]propanoyl]amino]acetyl]amino]-6-(1,3-dihydroxypropan-2-ylamino)-6-oxohexyl]-trimethylazanium	1129997: Binding affinity to CBX7 (unknown origin) by isothermal titration calorimetry assay	kd	4.1000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-(4-tert-butylphenyl)acetyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319522: Antagonist activity at recombinant human C-terminal His-tagged CBX7 chromodomain (8 to 62 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	4.4000	uM
[4-[2-[4-(2,3-dimethoxybenzoyl)piperazin-1-yl]-2-oxoethoxy]-2,6-dimethylphenyl]urea	1313552: Binding affinity to CBX7ChD (7 to 66 residues) (unknown origin) expressed in RIPL-BL21 (DE3)-CodonPlus competent cells in presence of FITC-labeled SETDB1-K1170me3/H3K27me3/ANRIL-LoopC RNA by fluorescence anisotropy assay	ki	4.8000	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-benzamido-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-[[(2S,3R)-3-hydroxy-1-[[(2S)-3-(1H-imidazol-5-yl)-1-[(2-methoxy-2-oxoethyl)amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1506814: Binding affinity to Cbx7 (unknown origin) by ITC method	kd	5.0000	uM

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	4
bisphenol A	decreases methylation, increases expression, affects cotreatment	3
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	3
sodium arsenite	increases expression	2
Resveratrol	decreases expression, decreases phosphorylation, decreases reaction, increases expression, affects cotreatment	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
triphenyl phosphate	affects expression	1
methylselenic acid	increases expression	1
trichostatin A	increases expression	1
arsenite	decreases reaction, affects binding	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
ferrous chloride	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	increases expression, affects cotreatment	1

ChEMBL screening assays

36 unique, capped per target: 35 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1767464	Binding	Binding affinity to CBX7 by chemiluminescent assay	Small-molecule ligands of methyl-lysine binding proteins. — J Med Chem
CHEMBL5723067	Functional	Affinity Biochemical interaction: (AlphaScreen) EUB0001090a CBX7	Affinity Biochemical Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1IP	HyCyte 786-O KO-hCBX7	Cancer cell line	Male
CVCL_E1IQ	HyCyte A-498 KO-hCBX7	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer